Marina Faedi

1.7k total citations · 1 hit paper
27 papers, 710 citations indexed

About

Marina Faedi is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Marina Faedi has authored 27 papers receiving a total of 710 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Marina Faedi's work include Glioma Diagnosis and Treatment (17 papers), Brain Metastases and Treatment (11 papers) and Cancer Treatment and Pharmacology (7 papers). Marina Faedi is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Brain Metastases and Treatment (11 papers) and Cancer Treatment and Pharmacology (7 papers). Marina Faedi collaborates with scholars based in Italy, United Kingdom and France. Marina Faedi's co-authors include Alba A. Brandes, Roberta Rudà, Riccardo Soffietti, Marica Eoli, Giuseppe Lombardi, Dino Amadori, Andrea Pace, Vittorina Zagonel, Francesco Pasqualetti and Miriam Farina and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Marina Faedi

25 papers receiving 702 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

2018 257 citations Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marina Faedi Italy	13	412	213	199	164	157	27	710
Debra C. LaFrankie United States	10	537 1.3×	201 0.9×	120 0.6×	180 1.1×	200 1.3×	19	701
Lidia Gatto Italy	21	334 0.8×	450 2.1×	342 1.7×	290 1.8×	326 2.1×	83	1.2k
Kara Penne United States	7	375 0.9×	203 1.0×	256 1.3×	154 0.9×	260 1.7×	11	691
H. I. Robins United States	11	284 0.7×	137 0.6×	126 0.6×	125 0.8×	235 1.5×	20	575
Fable Zustovich Italy	18	207 0.5×	528 2.5×	317 1.6×	214 1.3×	298 1.9×	87	949
Marco Bartolotti Italy	18	252 0.6×	554 2.6×	446 2.2×	143 0.9×	214 1.4×	33	897
Gaspar Reynés Spain	14	472 1.1×	219 1.0×	222 1.1×	232 1.4×	371 2.4×	40	898
Shannon Chang United States	14	635 1.5×	248 1.2×	196 1.0×	208 1.3×	281 1.8×	37	928
Nancy Iturria United States	8	661 1.6×	313 1.5×	519 2.6×	170 1.0×	779 5.0×	12	1.5k
Brian Haylock United Kingdom	17	654 1.6×	279 1.3×	227 1.1×	236 1.4×	259 1.6×	42	1.2k

Countries citing papers authored by Marina Faedi

Since Specialization

Citations

This map shows the geographic impact of Marina Faedi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Faedi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Faedi more than expected).

Fields of papers citing papers by Marina Faedi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Faedi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Faedi. The network helps show where Marina Faedi may publish in the future.

Co-authorship network of co-authors of Marina Faedi

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Faedi. A scholar is included among the top collaborators of Marina Faedi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Faedi. Marina Faedi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rudà, Roberta, Alessia Pellerino, Andrea Pace, et al.. (2019). Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. Journal of Neuro-Oncology. 145(1). 115–123. 24 indexed citations

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2018). Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 20(1). 110–119. 257 indexed citations breakdown →

Lombardi, Giuseppe, Gian Luca De Salvo, Roberta Rudà, et al.. (2018). Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology. 36(15_suppl). 2047–2047. 2 indexed citations

Pedretti, Sara, L. Masini, Luca Triggiani, et al.. (2018). OC-0587: Hypofractionated radiotherapy vs temozolomide in glioblastoma RPA V-VI: a randomized phase II trial. Radiotherapy and Oncology. 127. S307–S307.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2017). REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients. Annals of Oncology. 28. v610–v610. 3 indexed citations

Rocca, Andrea, Lorenzo Cecconetto, Alessandro Passardi, et al.. (2017). Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology. 79(5). 863–871. 15 indexed citations

Soffietti, Riccardo, Alessia Pellerino, Andrea Pace, et al.. (2017). ACTR-06. DOSE DENSE TEMOZOLOMIDE (TMZ) AS INITIAL TREATMENT FOR HIGH-RISK OLIGODENDROGLIAL TUMORS: LONG-TERM RESULTS OF A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY. Neuro-Oncology. 19(suppl_6). vi2–vi2. 1 indexed citations

Franceschi, Enrico, Roberta Depenni, Alexandro Paccapelo, et al.. (2016). Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Journal of Neuro-Oncology. 128(1). 157–162. 20 indexed citations

Brigliadori, Giovanni, Flavia Foca, Monia Dall’Agata, et al.. (2016). Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. Journal of Neuro-Oncology. 128(2). 333–339. 55 indexed citations

10.

Furtner, Julia, Veronika Schöpf, Katharina Seystahl, et al.. (2015). Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology. 18(3). 401–407. 42 indexed citations

11.

Mazza, Elena, Alba A. Brandes, Silvia Zanon, et al.. (2015). Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology. 77(1). 115–120. 28 indexed citations

12.

Farolfi, Alberto, Emanuela Scarpi, Andrea Rocca, et al.. (2015). Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. European Journal of Cancer. 51(14). 1874–1881. 20 indexed citations

13.

Farolfi, Alberto, Michele Aquilina, Emanuela Scarpi, et al.. (2013). Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 99(9). 634–639. 82 indexed citations

14.

Pasini, Alice, Emanuela Bianchi, Anna Maria Cremonini, et al.. (2012). LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. Oncology Reports. 28(6). 2271–2277. 10 indexed citations

15.

Rudà, Roberta, Luca Bertero, Elisa Trevisan, et al.. (2012). Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).. Journal of Clinical Oncology. 30(15_suppl). 2037–2037. 3 indexed citations

16.

Fabbri, Francesca, Alessandro Passardi, Alessandra Ravaioli, et al.. (2011). Sequential treatment strategy for metastatic colorectal cancer: A phase III study of chemotherapy (CT) with or without bevacizumab (Bev) as first-line therapy followed by two phase III studies of CT alone or CT plus bev with or without cetuximab (Cetux) as second-line therapy (ITACa Study IRST 153 01).. Journal of Clinical Oncology. 29(15_suppl). e14161–e14161. 2 indexed citations

17.

Amadori, Dino, Rosella Silvestrini, Mario De Lena, et al.. (2010). Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer. Breast Cancer Research and Treatment. 125(3). 775–784. 19 indexed citations

18.

Boccardo, Francesco, Dino Amadori, Pamela Guglielmini, et al.. (2010). Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer. Oncology. 78(3-4). 274–281. 12 indexed citations

19.

Brandes, Alba A., A. Tosoni, Enrico Franceschi, et al.. (2009). Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology. 64(4). 769–75. 73 indexed citations

20.

Ravaioli, Alessandra, Marina Faedi, G. Rosti, et al.. (1986). Primary gastric lymphoma: A review of 45 cases. European Journal of Cancer and Clinical Oncology. 22(12). 1461–1465. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact